TMO Stock Analysis: Thermo Fisher Scientific | NYSE
Diagnostics & Research | NYSE, USA | Market Cap: 243.412m USD | 12M Return: 39.2% | US8835561023 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 1.16B
EPS Trend: 90.5%
Qual. Beats: 4
Rev. Trend: 78.3%
Qual. Beats: 6
Warnings
No concerns identified
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Thermo Fisher Scientific Inc. (TMO) is a global supplier to the life sciences and healthcare industries, operating four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. Its offerings span reagents, instruments, consumables, clinical diagnostics (including allergy/autoimmune testing, microbiology, and transplant diagnostics), and outsourced services for pharmaceutical and clinical research customers in North America, Europe, and Asia-Pacific. The company was founded in 1956, is headquartered in Waltham, Massachusetts, and has been publicly listed since 1978.
The company sits within the Health Care sector, specifically the Life Sciences Tools & Services sub-industry, and functions largely as a diversified instrument-and-consumables vendor with a growing biopharma services franchise. Its business model combines recurring consumables and reagents revenue with higher-margin analytical instruments, supported by pharma services that address drug development and bioprocessing needs across academic, government, and industrial customers.
- Biopharma services revenue grows on clinical trial demand and pharma R&D budgets
- China biosecure legislation threatens life sciences demand exposure
- PPD integration and cost programs expand operating margins
| Net Income: 6.98b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.37 > 1.0 |
| NWC/Revenue: 17.90% < 20% (prev 27.46%; Δ -9.56% < -1%) |
| CFO/TA 0.08 > 3% & CFO 9.01b > Net Income 6.98b |
| Net Debt (38.5b) to EBITDA (10.9b): 3.52 < 3 |
| Current Ratio: 1.55 > 1.5 & < 3 |
| Outstanding Shares: last quarter (371.0m) vs 12m ago -1.85% < -2% |
| Gross Margin: 40.37% > 18% (prev 39.58%; Δ 0.79% > 0.5%) |
| Asset Turnover: 43.22% > 50% (prev 42.69%; Δ 0.54% > 0%) |
| Interest Coverage Ratio: 5.88 > 6 (EBIT TTM 8.63b / Interest Expense TTM 1.47b) |
| A: 0.07 (Total Current Assets 23.4b - Total Current Liabilities 15.1b) / Total Assets 113b |
| B: 0.55 (Retained Earnings 62.2b / Total Assets 113b) |
| C: 0.08 (EBIT TTM 8.63b / Avg Total Assets 107b) |
| D: 0.87 (Book Value of Equity 52.7b / Total Liabilities 60.5b) |
| Altman-Z'' = 3.73 = AA |
| DSRI: 0.88 (Receivables 9.45b/10.0b, Revenue 46.3b/43.2b) |
| GMI: 0.98 (GM 39.58% / 40.37%) |
| AQI: 1.06 (AQ_t 0.70 / AQ_t-1 0.66) |
| SGI: 1.07 (Revenue 46.3b / 43.2b) |
| TATA: -0.02 (NI 6.98b - CFO 9.01b) / TA 113b) |
| Beneish M = -3.06 (Cap -4..+1) = AA |
As of September 22, 2026, the stock is trading at USD 658.76 with a total of 2,303,501 shares traded. Over the past week, the price has changed by +7.44%, over one month by +4.77%, over three months by +42.08% and over the past year by +39.18%.
Current recommended Stop Loss: 622.90 (which is 5.4% or 2.3 ATR below the current price).
Thermo Fisher Scientific has received a consensus analysts rating of 4.39. Therefore, it is recommended to buy TMO.
- StrongBuy: 18
- Buy: 7
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 645.2 | -2.1% |
P/E Trailing = 34.8502
P/E Forward = 23.5849
P/S = 5.2532
P/B = 4.5512
P/EG = 1.9313
Revenue TTM = 46.3b USD
EBIT TTM = 8.63b USD
EBITDA TTM = 10.9b USD
Long Term Debt = 39.2b USD (from longTermDebt, last quarter)
Short Term Debt = 3.37b USD (from shortTermDebt, last quarter)
Debt = 42.5b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 38.5b USD (calculated: Debt 42.5b - CCE 4.06b)
Enterprise Value = 282b USD (243b + Debt 42.5b - CCE 4.06b)
Interest Coverage Ratio = 5.88 (Ebit TTM 8.63b / Interest Expense TTM 1.47b)
EV/FCF = 38.52x (Enterprise Value 282b / FCF TTM 7.32b)
FCF Yield = 2.60% (FCF TTM 7.32b / Enterprise Value 282b)
FCF Margin = 15.79% (FCF TTM 7.32b / Revenue TTM 46.3b)
Net Margin = 15.06% (Net Income TTM 6.98b / Revenue TTM 46.3b)
Gross Margin = 40.37% ((Revenue TTM 46.3b - Cost of Revenue TTM 27.6b) / Revenue TTM)
Gross Margin QoQ = 41.21% (prev 40.67%)
Tobins Q-Ratio = 2.49 (Enterprise Value 282b / Total Assets 113b)
Interest Expense / Debt = 3.45% (Interest Expense 1.47b / Debt 42.5b)
Taxrate = 7.85% (597.0m / 7.61b)
NOPAT = 7.95b (EBIT 8.63b * (1 - 7.85%))
Current Ratio = 1.55 (Total Current Assets 23.4b / Total Current Liabilities 15.1b)
Debt / Equity = 0.81 (Debt 42.5b / totalStockholderEquity, last quarter 52.7b)
Debt / EBITDA = 3.52 (Net Debt 38.5b / EBITDA 10.9b)
Debt / FCF = 5.26 (Net Debt 38.5b / FCF TTM 7.32b)
Total Stockholder Equity = 52.3b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.51% (Net Income 6.98b / Total Assets 113b)
RoE = 13.35% (Net Income TTM 6.98b / Total Stockholder Equity 52.3b)
RoCE = 9.44% (EBIT 8.63b / Capital Employed (Equity 52.3b + L.T.Debt 39.2b))
RoIC = 8.02% (NOPAT 7.95b / Invested Capital 99.2b)
WACC = 7.22% (E(243b)/V(286b) * Re(7.93%) + D(42.5b)/V(286b) * Rd(3.45%) * (1-Tc(0.08)))
Discount Rate = 7.93% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -95.55 | Cagr: -1.52%
[DCF] Terminal Value 77.97% ; FCFF base≈6.86b ; Y1≈7.86b ; Y5≈11.6b
[DCF] Fair Price = 366.9 (EV 174b - Net Debt 38.5b = Equity 136b / Shares 369.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 90.54 | EPS CAGR: 3.54% | SUE: 3.52 | # QB: 4
Revenue Correlation: 78.31 | Revenue CAGR: 2.47% | SUE: 2.90 | # QB: 6
EPS current Quarter (2026-09-30): EPS=6.41 | Chg30d=+0.05% | Revisions=+32% | Analysts=22
EPS current Year (2026-12-31): EPS=25.13 | Chg30d=+0.05% | Revisions=+89% | GrowthEPS=+9.9% | GrowthRev=+7.4%
EPS next Year (2027-12-31): EPS=27.53 | Chg30d=+0.08% | Revisions=+74% | GrowthEPS=+9.6% | GrowthRev=+5.1%
[Analyst] Revisions Ratio: +73% (up=59, down=8)